Related Experiment Video
Updated: Oct 10, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer
Danielle Brazel1, Misako Nagasaka1,2,3
1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, USA.
Abstract:
Non-small cell lung cancer (NSCLC) patients demonstrating sensitizing oncogenic driver mutations have derived clinical benefit from targeted therapy. EGFR mutations constitutively activate the signaling pathway, leading to prosurvival and antiapoptotic signals. Classic sensitizing EGFR mutations, such as exon 19 deletions and exon 21 L858R point mutations, respond well to tyrosine kinase inhibitors (TKIs). On the other hand, EGFR exon 20 in-frame insertions are observed in 4-12% of EGFR-mutated NSCLC and are resistant to targeted therapy with TKIs. In May 2021, the Federal Drug Administration (FDA) provided accelerated approval to amivantamab (Rybrevant) in adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations after treatment with platinum-based chemotherapy. Here, we discuss properties of amivantamab, clinical trial results, and management of patients with EGFR exon 20 insertion mutated NSCLC.
Insights
Amivantamab offers a new targeted therapy for non-small cell lung cancer (NSCLC) patients with specific EGFR exon 20 insertions, a group resistant to traditional tyrosine kinase inhibitors (TKIs). This FDA-approved treatment provides a crucial option for advanced NSCLC.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations benefits from targeted therapy.
- EGFR exon 20 in-frame insertions are resistant to standard tyrosine kinase inhibitors (TKIs).
- EGFR exon 20 insertions represent 4-12% of EGFR-mutated NSCLC cases.
Purpose of the Study:
- To discuss amivantamab, a targeted therapy for NSCLC.
- To review clinical trial outcomes for amivantamab.
- To outline the management of NSCLC patients with EGFR exon 20 insertion mutations.
Main Methods:
- Review of amivantamab properties.
- Analysis of clinical trial data for amivantamab efficacy and safety.
- Discussion of patient management strategies.
Main Results:
- Amivantamab received FDA accelerated approval in May 2021.
- The drug is indicated for advanced or metastatic NSCLC with EGFR exon 20 insertions post-chemotherapy.
- Clinical trials demonstrate amivantamab's efficacy in this patient population.
Conclusions:
- Amivantamab provides a vital treatment option for NSCLC patients with EGFR exon 20 insertion mutations.
- Targeted therapy for specific EGFR mutations continues to evolve.
- Further research and clinical management are essential for optimizing outcomes.
More Related Videos
09:49Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:23Abnormal Proliferation